Veru (VERU)
(Delayed Data from NSDQ)
$1.47 USD
+0.14 (10.53%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.47 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
Veru Inc. [VERU]
Reports for Purchase
Showing records 41 - 60 ( 92 total )
Company: Veru Inc.
Industry: Medical - Products
Top- and Bottom-Line Beat in F3Q21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Sabizabulin Phase 3 Prostate Cancer Trial Starts Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
VERU-100 Phase 2 Prostate Cancer Trial Starts Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Clinical Data in Breast and Prostate Cancer Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 3 COVID-19 Trial Starts Patient Recruitment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
TADFIN Approval Decision in Late 2021; F2Q21 Financial Results; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
FDA Authorizes Advancement of Phase 3 COVID-19 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
TADFIN New Drug Application Submitted; Equity Financing; Reiterate Buy; Adjusting PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Record Sales in F1Q20; Reiterate Buy; Raising PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
VERU-111 Positive High-Risk COVID-19 Phase 2 Data; Raising PT to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Enobosarm Preclinical Data in Breast Cancer Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Survival Benefit in Heavily Pretreated Breast Cancer; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Fiscal Year 2020 Financial Results Reported; Reiterate Buy; Raising PT to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
VERU-111 Phase 2 Prostate Cancer Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
F3Q20 Financial Results; VERU-111 Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
In Vitro Study Confirms Reduction of Key Cytokines by VERU-111; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
VERU-111 Phase 3 Prostate Cancer Trial Design Gets Positive FDA Feedback; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
Phase 2 COVID-19 Trial Enrolls First Patient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
F2Q20 Financial Results; COVID-19 Trial Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Veru Inc.
Industry: Medical - Products
VERU-111 Positive Phase 1b Preliminary Prostate Cancer Study Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y